Soleno Therapeutics Inc (SLNO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has a cash flow conversion efficiency ratio of 0.052x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($25.98 Million) by net assets ($495.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Soleno Therapeutics Inc (SLNO) balance sheet quality index to measure how much of total assets are equity-financed.
Soleno Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SLNO operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Soleno Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Soleno Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IHS Holding Ltd
NYSE:IHS
|
-8.679x |
|
Four Corners Property Trust Inc
NYSE:FCPT
|
0.028x |
|
Jiangsu Sidike New Materials Sci Te
SHE:300806
|
0.047x |
|
AIMA Technology Group Co Ltd
SHG:603529
|
0.294x |
|
Easy Click Worldwide Network Technology Co. Ltd. A
SHE:301171
|
-0.024x |
|
Doximity Inc
NYSE:DOCS
|
0.115x |
|
Kaynes Technology India Limited
NSE:KAYNES
|
-0.046x |
|
Steadfast Group Limited
F:1S6
|
0.055x |
Annual Cash Flow Conversion Efficiency for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Soleno Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Soleno Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $450.12 Million | $46.80 Million | 0.104x | +136.88% |
| 2024-12-31 | $245.11 Million | $-69.10 Million | -0.282x | -78.03% |
| 2023-12-31 | $157.51 Million | $-24.94 Million | -0.158x | +92.12% |
| 2022-12-31 | $10.35 Million | $-20.78 Million | -2.008x | -28.67% |
| 2021-12-31 | $17.79 Million | $-27.77 Million | -1.561x | -181.82% |
| 2020-12-31 | $45.55 Million | $-25.22 Million | -0.554x | +52.36% |
| 2019-12-31 | $14.95 Million | $-17.38 Million | -1.162x | -202.60% |
| 2018-12-31 | $30.41 Million | $-11.68 Million | -0.384x | -2.45% |
| 2017-12-31 | $26.53 Million | $-9.95 Million | -0.375x | +90.46% |
| 2016-12-31 | $3.44 Million | $-13.50 Million | -3.929x | -22.99% |
| 2015-12-31 | $3.22 Million | $-10.30 Million | -3.195x | -836.12% |
| 2014-12-31 | $-10.33 Million | $-4.48 Million | 0.434x | +1756.41% |
| 2013-12-31 | $-37.86 Million | $-885.22K | 0.023x | -77.14% |
| 2012-12-31 | $-34.20 Million | $-3.50 Million | 0.102x | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more